09.30.25 -- Lilly's Kinsale Facility Provides A Benchmark For Your CDMO Selection

Discover the latest in analytical services for cell and gene therapies on Oct. 6 at the Analytical Services session of the Outsourced Pharma Capacity Update. This virtual event features concise presentations, live Q&As, and insights into assay development, method validation, and analytical platforms. Designed for biopharma professionals and investors, it connects you — from the convenience of your computer — with CDMOs that have the capabilities and available capacity to support your therapeutic pipeline. Save your spot today!

Accelerate the development of high-quality biopharmaceuticals by implementing phase-appropriate, risk-based manufacturing and testing strategies that ensure timely progression.

Discover an essential aspect of development that ensures gene therapy products remain safe, stable, and effective throughout preparation and administration by simulating real-world clinical conditions.

This study evaluates filter trains from four vendors, aiming to enhance titer recovery, HCP removal, DNA breakthrough, turbidity reduction, and throughput in gene therapy manufacturing.

Interleukins help optimize therapeutic outcomes in cancer immunotherapy and regenerative medicine. Manufacturing success requires stringent control over production, formulation, and stability to ensure safety and efficacy.

Review the advantages and limitations of transcriptional assays versus reporter gene assays and how the transcriptional assay compares to ddPCR and flow cytometry for analysis of CGTs.

Drive the next wave of cell and gene therapy innovation by overcoming operational, funding, and regulatory challenges to deliver life-changing treatments to patients faster.

Explore the development work involved for the individual technologies that make up an innovative and scalable, chemical-free continuous viral vector production platform.

Consider how the following strategies can be used to optimize AAV manufacturing by reducing risk and balancing productivity, quality, and cost to meet the growing demands of gene therapy.

Learn how one family's collaboration with a specialized CDMO enabled the rapid development of a life-saving gene therapy for their daughter diagnosed with an ultra-rare disease.

Our team of experts can help you navigate the complex manufacturing and development lifecycle for cell and gene therapies from bench to bedside.

With a robust track record of more than 7,500 GMP batches and proven platforms for multiple modalities, we pride ourselves on delivering speed, scalability, and reliability.

Gain a comprehensive understanding of the biochemical composition of each vector batch while minimizing product consumption, ensuring efficiency and precision in analysis.

As the pipeline of viral vector-based therapies continues to reach later-stage studies, a standardized manufacturing process is necessary for CMC requirements from regulatory agencies.